Alpha 1-antitrypsin deficiency screening: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(13 intermediate revisions by 4 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Alpha 1-antitrypsin deficiency}}
{{Alpha 1-antitrypsin deficiency}}
{{CMG}}
{{CMG}}; {{AE}} {{Mazia}}


==Overview==
==Overview==
According to the Spanish Society of Pneumology and Thoracic Surgery (SEPAR), all [[Chronic obstructive pulmonary disease|COPD]] [[patients]] should be [[Screening|screened]] for AATD at least once in their lifetime. All [[patients]] with unexplained [[Liver diseases|liver disease]] with or without [[Respiratory|respiratory symptoms]] should be evaluated for AATD.


==Screening==
==Screening==
 
[[Screening]] for alpha 1-antitrypsin deficiency includes:<ref name="pmid29225784">{{cite journal |vauthors=Hersh CP |title=Diagnosing alpha-1 antitrypsin deficiency: the first step in precision medicine |journal=F1000Res |volume=6 |issue= |pages=2049 |year=2017 |pmid=29225784 |pmc=5710307 |doi=10.12688/f1000research.12399.1 |url=}}</ref><ref name="pmid28929906">{{cite journal |vauthors=Lascano JE, Campos MA |title=The important role of primary care providers in the detection of alpha-1 antitrypsin deficiency |journal=Postgrad Med |volume=129 |issue=8 |pages=889–895 |year=2017 |pmid=28929906 |doi=10.1080/00325481.2017.1381539 |url=}}</ref>
*According to the Spanish Society of Pneumology and Thoracic Surgery (SEPAR), all [[Chronic obstructive pulmonary disease|COPD]] [[patients]] should be [[Screening (medicine)|screened]] for AATD at least once in their lifetime.
*All patients with unexplained [[Liver diseases|liver disease]] with or without [[Respiratory|respiratory symptoms]] should be evaluated for AATD.
*Adults with [[necrotizing]] [[panniculitis]] should be screened.


==References==
==References==
{{Reflist|2}}
{{Reflist|2}}


[[Category:Needs content]]
[[Category:Gastroenterology]]
[[Category:Gastroenterology]]
[[Category:Genetic disorders]]
[[Category:Pulmonology]]
[[Category:Pulmonology]]
[[Category:Hepatology]]
[[Category:Hepatology]]
[[Category:Inborn errors of metabolism]]
[[Category:Metabolic disorders]]
[[Category:Overview complete]]
[[Category:Disease]]


{{WH}}
{{WikiDoc Help Menu}}
{{WS}}
{{WikiDoc Sources}}

Latest revision as of 17:46, 22 January 2018

Alpha 1-antitrypsin deficiency Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Alpha 1-antitrypsin deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Alpha 1-antitrypsin deficiency screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Alpha 1-antitrypsin deficiency screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Alpha 1-antitrypsin deficiency screening

CDC on Alpha 1-antitrypsin deficiency screening

Alpha 1-antitrypsin deficiency screening in the news

Blogs on Alpha 1-antitrypsin deficiency screening

Directions to Hospitals Treating Alpha 1-antitrypsin deficiency

Risk calculators and risk factors for Alpha 1-antitrypsin deficiency screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mazia Fatima, MBBS [2]

Overview

According to the Spanish Society of Pneumology and Thoracic Surgery (SEPAR), all COPD patients should be screened for AATD at least once in their lifetime. All patients with unexplained liver disease with or without respiratory symptoms should be evaluated for AATD.

Screening

Screening for alpha 1-antitrypsin deficiency includes:[1][2]

References

  1. Hersh CP (2017). "Diagnosing alpha-1 antitrypsin deficiency: the first step in precision medicine". F1000Res. 6: 2049. doi:10.12688/f1000research.12399.1. PMC 5710307. PMID 29225784.
  2. Lascano JE, Campos MA (2017). "The important role of primary care providers in the detection of alpha-1 antitrypsin deficiency". Postgrad Med. 129 (8): 889–895. doi:10.1080/00325481.2017.1381539. PMID 28929906.


Template:WikiDoc Sources